UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Cancer-Associated Fibroblasts in Gastrointestinal Cancers: Unveiling Their Dynamic Roles in the Tumor Microenvironment

International journal of molecular sciences, 2023-11, Vol.24 (22), p.16505

2023

Volltextzugriff (PDF)

The impact of IDH and NAT2 gene polymorphisms in acute myeloid leukemia risk and overall survival in an Arab population: A case-control study

PloS one, 2023-07, Vol.18 (7), p.e0289014-e0289014

2023

Volltextzugriff (PDF)

Identification of Hypoxia Prognostic Signature in Glioblastoma Multiforme Based on Bulk and Single-Cell RNA-Seq

Cancers, 2024-02, Vol.16 (3), p.633

2024

Volltextzugriff (PDF)

Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach

Cancers, 2022-11, Vol.14 (22), p.5605

2022

Volltextzugriff (PDF)

Clinical and radiologic differences between early onset, late onset, and very late onset adult multiple sclerosis

Multiple sclerosis and related disorders, 2023-12, Vol.80, p.105132-105132, Article 105132

2023

Volltextzugriff (PDF)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis

Cancers, 2024-02, Vol.16 (5), p.900

2024

Volltextzugriff (PDF)

Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance

Cancer treatment and research communications, 2022, Vol.33, p.100643-100643, Article 100643

2022

Volltextzugriff (PDF)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

Clinical hematology international, 2022-06, Vol.4 (1-2), p.21-29

2022

Volltextzugriff (PDF)

Management of chronic subdural hematoma: A study from Jordan

Journal of Taibah University Medical Sciences, 2022-12, Vol.17 (6), p.1021-1030

2022

Volltextzugriff (PDF)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials

EJHaem, 2023-05, Vol.4 (2), p.454-458

2023

Volltextzugriff (PDF)

Pathological response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer (NSCLC): A systematic review and meta-analysis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e20582-e20582

2022

Volltextzugriff (PDF)

The effect of radioactive iodine (RAI) on disease-specific survival in differentiated thyroid cancer (DTC): A study of 96,557 patients

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18095-e18095

2023

Volltextzugriff (PDF)

Clinicopathological characteristics and survival outcomes for testicular choriocarcinoma and non-testicular choriocarcinoma: A SEER database analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17026-e17026

2023

Volltextzugriff (PDF)

Next generation immuno-oncology biomarkers in gastrointestinal cancer: what does the future hold?

Expert review of molecular diagnostics, 2023-10, Vol.23 (10), p.863-873

2023

Volltextzugriff (PDF)

Deep brain stimulation targets in epilepsy: Systematic review and meta‐analysis of anterior and centromedian thalamic nuclei and hippocampus

Epilepsia (Copenhagen), 2022-07, Vol.63 (7), p.1883-1884

2022

Volltextzugriff (PDF)

The Use and Reporting of Cytogenetics in Phase III Multiple Myeloma Clinical Trials

Blood, 2022-11, Vol.140 (Supplement 1), p.12532-12533

2022

Volltextzugriff (PDF)

Variability of Definition of High-Risk Multiple Myeloma in Phase III Clinical Trials

Blood, 2022-11, Vol.140 (Supplement 1), p.10116-10117

2022

Volltextzugriff (PDF)

Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival

Surgery today (Tokyo, Japan), 2023-03, Vol.53 (3), p.279-292

2023

Volltextzugriff (PDF)

Anti-neoplastic drugs for malignant pleural effusion in non-small cell lung cancer: A meta-analysis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21060-e21060

2022

Volltextzugriff (PDF)

First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis

American journal of hematology, 2022-07, Vol.97 (7), p.942-950

2022

Volltextzugriff (PDF)

Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8059-8059

2023

Volltextzugriff (PDF)

Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20053-e20053

2023

Volltextzugriff (PDF)

Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma

American journal of hematology, 2024-08

2024

Volltextzugriff (PDF)

OA-42 Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma treated on earlier total therapy protocols

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S25-S26

2023

Volltextzugriff (PDF)

Predictors of early and late postoperative seizures in meningioma patients: a systematic review and meta-analysis

Neurosurgical review, 2024-05, Vol.47 (1), p.242-242, Article 242

2024

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Cancer-Associated Fibroblasts in Gastrointestinal Cancers: Unveiling Their Dynamic Roles in the Tumor Microenvironment

The impact of IDH and NAT2 gene polymorphisms in acute myeloid leukemia risk and overall survival in an Arab population: A case-control study

Identification of Hypoxia Prognostic Signature in Glioblastoma Multiforme Based on Bulk and Single-Cell RNA-Seq

Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach

Clinical and radiologic differences between early onset, late onset, and very late onset adult multiple sclerosis

The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis

Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

Management of chronic subdural hematoma: A study from Jordan

Variability of definition of high‐risk multiple myeloma across phase III clinical trials

Pathological response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer (NSCLC): A systematic review and meta-analysis

The effect of radioactive iodine (RAI) on disease-specific survival in differentiated thyroid cancer (DTC): A study of 96,557 patients

Clinicopathological characteristics and survival outcomes for testicular choriocarcinoma and non-testicular choriocarcinoma: A SEER database analysis

Next generation immuno-oncology biomarkers in gastrointestinal cancer: what does the future hold?

Deep brain stimulation targets in epilepsy: Systematic review and meta‐analysis of anterior and centromedian thalamic nuclei and hippocampus

The Use and Reporting of Cytogenetics in Phase III Multiple Myeloma Clinical Trials

Variability of Definition of High-Risk Multiple Myeloma in Phase III Clinical Trials

Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival

Anti-neoplastic drugs for malignant pleural effusion in non-small cell lung cancer: A meta-analysis

First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis

Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols

Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB

Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma

OA-42 Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma treated on earlier total therapy protocols

Predictors of early and late postoperative seizures in meningioma patients: a systematic review and meta-analysis

Suchergebnisse filtern